Alnylam Pharmaceuticals (ALNY) ESC Congress Presentation summary
Event summary combining transcript, slides, and related documents.
ESC Congress Presentation summary
1 Sep, 2026TTR leadership and strategic vision
Positioned for durable leadership in TTR with AMVUTTRA and nucresiran, leveraging strong clinical data and broad access in the U.S.
AMVUTTRA is established as a foundational, first-line therapy for ATTR-CM, with >50% share of new starts among experienced prescribers.
Over 1,700 new prescribers since launch and >90% first-line access with minimal out-of-pocket costs for most patients.
Ambition to achieve global TTR market leadership and launch next-gen silencer nucresiran in CM by 2030.
Targeting 25%+ total revenue CAGR and ~30% non-GAAP operating margin through 2030.
Clinical innovation and pipeline progress
HELIOS-B data support AMVUTTRA’s efficacy, showing significant reductions in all-cause mortality and cardiovascular events, especially when initiated early.
TRITON-CM trial designed for success with deep TTR knockdown, early patient population, and event-driven endpoints.
Nucresiran aims for highest-ever TTR knockdown, with modeling suggesting deeper knockdown correlates with better outcomes.
RNAi therapeutics have demonstrated additive benefit on top of stabilizer therapy in multiple studies.
Multiple late-stage readouts expected in 2H26, including programs in Huntington’s disease and obesity.
Market performance and growth drivers
Quarterly sales post-AMVUTTRA CM launch show strong revenue growth, with AMVUTTRA leading among products.
ATTR-CM category expected to grow, with ~15,000 new patients annually and ~75,000 treated by 2030.
Driving breadth of prescribers and broad payer access are key to unlocking next growth wave.
Continued investment in R&D (~30% of revenues) to deliver new transformative medicines beyond TTR.
RNAi platform offers differentiated clinical and commercial advantages over ASO competitors.
Latest events from Alnylam Pharmaceuticals
- AMVUTTRA adoption and 2027 access shifts shape near-term priorities; TRITON-CM targets ~2030.ALNY
Jefferies Global Healthcare Conference - TTR-led product growth lifted Q3 revenue 52%; a tax benefit boosted net income.ALNY
Q3 2026 - Brezosiran lowered CSF mHTT by up to 64%; a pivotal study is planned for 2027.ALNY
Investor update - AMVUTTRA’s strong growth and robust pipeline drive optimism for future expansion and innovation.ALNY
Morgan Stanley 24th Annual Global Healthcare Conference - Zilebesiran offers sustained BP control and CV risk reduction with twice-yearly dosing.ALNY
Investor update - Strong AMVUTTRA growth, reduced competition, and advancing pipeline drive optimism for future performance.ALNY
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 revenues jumped 74% to $1.2B, driven by AMVUTTRA and TTR franchise growth.ALNY
Q2 2026 - Vutrisiran demonstrated robust mortality reduction and is poised for a major Q2 2025 launch.ALNY
2024 Wells Fargo Healthcare Conference - Cardiomyopathy launch fueled record growth and upgraded guidance, with robust pipeline momentum.ALNY
Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum